Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Length constant

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Length constant. Displaying page 1 of 1.
    EudraCT Number: 2020-001601-23 Sponsor Protocol Number: s63950 Start Date*: 2020-06-18
    Sponsor Name:University Hospitals of Leuven
    Full Title: Pharmacokinetics of apixaban in patients with short bowel syndrome requiring long term parenteral nutrition
    Medical condition: theoretically none (PK study), but drug is used for prevention or treatment of VTE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002010-35 Sponsor Protocol Number: TinnEx Start Date*: 2006-12-14
    Sponsor Name:Prof. Herta Flor, Head of the Institute of Clinical and Cognitive Neuroscience
    Full Title: An Extinction Training in Tinnitus
    Medical condition: The effect of pregabalin on the success to reduce the interference by tinnitus by an extinction training is tested in chronic tinnitus sufferers.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001430-35 Sponsor Protocol Number: 35RC19_8860_FLUDROSEPSIS Start Date*: 2021-04-21
    Sponsor Name:CHU Rennes
    Full Title: Evaluation of the hemodynamic effects of fludrocortisone on the pressive response to norepinephrine in patients in septic shock
    Medical condition: septic shock
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004565-14 Sponsor Protocol Number: ECP-002e Start Date*: 2014-02-13
    Sponsor Name:Edimer Pharmaceuticals, Inc.
    Full Title: Extension Study of XLHED-Affected Male Subjects treated with EDI200 in Protocol ECP-002
    Medical condition: X-linked hypohidrotic ectodermal dysplasia (XLHED) is caused by inherited defects in the ectodysplasin (EDA) gene that disrupt synthesis and/or function of the primary translational product EDA-A1....
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10072592 Hypohidrotic ectodermal dysplasia LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male
    Trial protocol: DE (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001936-86 Sponsor Protocol Number: COMET Start Date*: 2020-10-19
    Sponsor Name:Hannover Medical School
    Full Title: A prospective, randomized, open label Phase 2 clinical trial to evaluate superiority of anti-SARS-CoV-2 convalescent plasma versus standard-of-care in hospitalized patients with mild COVID-19
    Medical condition: Hospitalized patients with mild SARS-CoV-2 infection (WHO R&D Blueprint Ordinal Scale for Clinical Improvement = 3 or 4)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-005213-11 Sponsor Protocol Number: NES103694 Start Date*: 2005-03-31
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-centre, randomised, double-blind, parallel group study assessing the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with a...
    Medical condition: Acute decompensated heart failure (adHF)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10000803 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) IE (Completed) SK (Completed) HU (Prematurely Ended) IS (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) DK (Completed) LV (Completed) EE (Completed) FI (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002182-36 Sponsor Protocol Number: VRX-RET-E22-302 Start Date*: 2006-04-18
    Sponsor Name:Valeant Research & Development
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP PHASE 3 STUDY TO DETERMINE THE EFFICACY AND SAFETY OF TWO DOSES OF RETIGABINE (900 MG/DAY AND 600 MG/DAY) USED AS ADJUNCT...
    Medical condition: Refractory Epilepsy Patients with Partial-Onset Seizures
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) ES (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004363-21 Sponsor Protocol Number: 1042-0603 Start Date*: 2015-03-11
    Sponsor Name:Marinus Pharmaceuticals, Inc
    Full Title: A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Foll...
    Medical condition: Drug-Resistant Epilepsy with Partial-Onset Seizures
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10065336 Partial epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000825-35 Sponsor Protocol Number: U1111-1167-2731 Start Date*: 2015-08-27
    Sponsor Name:Rigshospitalet Blegdamsvej
    Full Title: The effect of the glucagon-like peptide-1 analogue, liraglutide (Victoza®), on jejunostomy output and intestinal absorption in short bowel syndrome patients, a double-blind cross-over study
    Medical condition: Short bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytes; ...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003571-12 Sponsor Protocol Number: GLU0409 Start Date*: 2006-11-15
    Sponsor Name:Barts and the London NHS Trust
    Full Title: Breath Methionine and Other Indices of Oxidant Stress in the Critical Care Setting. The effect of two doses of Dipeptiven given independently of parenteral nutrition.
    Medical condition: 60 consecutive critically ill patients will be recruited with illnesses such as severe infection, trauma and post-surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-004279-15 Sponsor Protocol Number: TAK-620-2004 Start Date*: 2022-09-02
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3, open-label, single-arm, repeated-dose study to evaluate the safety and tolerability, pharmacokinetics, and antiviral activity of maribavir for the treatment of cytomegalovirus (CMV) in...
    Medical condition: Cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021829 Infection in solid organ transplant recipients LLT
    20.0 100000004862 10021819 Infection in marrow transplant recipients LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) DE (Trial now transitioned) Outside EU/EEA FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006038-37 Sponsor Protocol Number: TAK-573-1501 Start Date*: 2022-10-11
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refr...
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) DE (Prematurely Ended) FR (Completed) IE (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004615-45 Sponsor Protocol Number: BPR-PIP-002 Start Date*: 2016-12-02
    Sponsor Name:Basilea Pharmaceutica International Ltd
    Full Title: A multicentre, randomized, investigator-blind, active-controlled study to evaluate the safety, tolerability, pharmacokinetics and efficacy of ceftobiprole versus intravenous standard-of-care cephal...
    Medical condition: Hospital-acquired pneumonia or community-acquired pneumonia requiring hospitalisation.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10010120 Community acquired pneumonia LLT
    19.0 100000004862 10052596 Nosocomial pneumonia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001150-15 Sponsor Protocol Number: MD1003CT2015-01-SERENDEM Start Date*: 2016-03-14
    Sponsor Name:MEDDAY PHARMACEUTICALS
    Full Title: SERENDEM study: MD1003 in patients suffering from demyelinating neuropathies, an open label pilot study
    Medical condition: chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating neuropathy associated with immunoglobulin M (IgM) monoclonal gammopathy and antibodies against myelin-associated glycoprotei...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10066137 Anti-MAG neuropathy LLT
    18.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    18.1 100000004850 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005644-26 Sponsor Protocol Number: 1.2012 Start Date*: 2014-12-23
    Sponsor Name:Atrium Medical Centre
    Full Title: Administration of intranvenous ferric carboxymaltose to children with IBD
    Medical condition: Anemia in children with Inflammatory Bowel Disease (IBD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004707-43 Sponsor Protocol Number: PP06489 Start Date*: 2018-08-09
    Sponsor Name:PledPharma AB
    Full Title: A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in th...
    Medical condition: Chemotherapy induced peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10079545 Chemotherapy induced peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Completed) GB (Completed) ES (Temporarily Halted) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:23:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA